ClinicaliQ Trial Snapshot
- A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) — Active Not Recruiting • Phase I • NCT05784441.
- New drug JNJ-90009530 tested in patients with hard-to-treat B-cell lymphoma to find safe doses and whether it works.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients. * will JNJ-90009530 help patients achieve a response and for how long? Conditions: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Interventions: JNJ-90009530 Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 21 participants